**CASE SCENARIO 1**

9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy.

9/10/13 anterior and posterior shave biopsies of the scalp lesion:

* Anterior biopsy: Malignant melanoma, superficial spreading type, invasive to Clark level IV, Breslow depth 0.92 mm, non-ulcerated, vertical growth phase present, mitotic rate of 4/mm2, tumor infiltrating lymphocytes are non-brisk, no perineural or LVI present, peripheral and deep margins positive
* Posterior biopsy: Melanoma in situ

10/9/13 Radical resection scalp melanoma with 1 cm margins and sentinel lymph node biopsy: Residual invasive malignant melanoma with extensive in situ component identified. Surgical margins of excision are widely negative; 0/2 sentinel nodes are positive; 0/1 jugulodiagastric node positive; 0/1 IIB sentinel nodes positive.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 1 Worksheet** | | | | | | | | |
| **Primary Site C\_\_ \_\_.\_\_** | | **Morphology \_\_ \_\_ \_\_ \_\_/\_\_ \_\_** | | | | **Laterality \_\_** | | |
| **Stage/ Prognostic Factors** | | | | | | | | |
| CS Tumor Size |  | | | | CS SSF 9 | | 988 | |
| CS Extension |  | | | | CS SSF 10 | | 988 | |
| CS Tumor Size/Ext Eval |  | | | | CS SSF 11 | | 988 | |
| CS Lymph Nodes |  | | | | CS SSF 12 | | 988 | |
| CS Lymph Nodes Eval |  | | | | CS SSF 13 | | 988 | |
| Regional Nodes Positive |  | | | | CS SSF 14 | | 988 | |
| Regional Nodes Examined |  | | | | CS SSF 15 | | 988 | |
| CS Mets at Dx |  | | | | CS SSF 16 | | 988 | |
| CS Mets Eval |  | | | | CS SSF 17 | | 988 | |
| CS SSF 1 |  | | | | CS SSF 18 | | 988 | |
| CS SSF 2 |  | | | | CS SSF 19 | | 988 | |
| CS SSF 3 |  | | | | CS SSF 20 | | 988 | |
| CS SSF 4 |  | | | | CS SSF 21 | | 988 | |
| CS SSF 5 |  | | | | CS SSF 22 | | 988 | |
| CS SSF 6 |  | | | | CS SSF 23 | | 988 | |
| CS SSF 7 |  | | | | CS SSF 24 | | 988 | |
| CS SSF 8 |  | | | | CS SSF 25 | | 988 | |
| Summary Stage  1 – Localized |  | | | | Derived AJCC TNM Stage (indicate c or p in the space before the T, N, or M) | |  | |
| Clinical AJCC TNM Stage |  | | | | Pathologic AJCC TNM Stage | |  | |
| **Treatment** | | | | | | | | |
| Diagnostic Staging Procedure | | |  |  | | | |  |
| **Surgery Codes** | | |  | **Radiation Codes** | | | |  |
| Surgical Procedure of Primary Site | | |  | Radiation Treatment Volume | | | |  |
| Scope of Regional Lymph Node Surgery | | |  | Regional Treatment Modality | | | |  |
| Surgical Procedure/ Other Site | | |  | Regional Dose | | | |  |
| **Systemic Therapy Codes** | | |  | Boost Treatment Modality | | | |  |
| Chemotherapy | | |  | Boost Dose | | | |  |
| Hormone Therapy | | |  | Number of Treatments to Volume | | | |  |
| Immunotherapy | | |  | Reason No Radiation | | | |  |
| Hematologic Transplant/Endocrine Procedure | | |  | Radiation/Surgery Sequence | | | |  |
| Systemic/Surgery Sequence | | |  |  | | | |  |

**CASE SCENARIO 2**

6/21/13 HISTORY: 66 year-old white female presented for her yearly skin exam. She had a suspicious lesion on her right lower calf. No lymphadenopathy present.

6/21/13 Shave biopsy of right lower calf: Lentigo maligna melanoma; Breslow depth 0.17 mm; Clark level II; no ulceration; no regression; mitotic rate less than 1/mm2; no LVI or perineural invasion; lateral margins positive.

7/3/13 Wide local excision of right lower calf lesion with excision margin just over 3 cm: Malignant melanoma, lentigo maligna type; tumor invades to Clark level II and Breslow depth 0.55 mm; non-ulcerated and RGP present; mitotic rate is 0/mm2; no regression, no microsatellite tumor nodules; negative margins.

7/3/13 It was recommended that patient see an oncologist post-op, but the patient declined.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 2 Worksheet** | | | | | | | | |
| **Primary Site C\_\_ \_\_.\_\_** | | **Morphology \_\_ \_\_ \_\_ \_\_/\_\_ \_\_** | | | | **Laterality \_\_** | | |
| **Stage/ Prognostic Factors** | | | | | | | | |
| CS Tumor Size |  | | | | CS SSF 9 | | 988 | |
| CS Extension |  | | | | CS SSF 10 | | 988 | |
| CS Tumor Size/Ext Eval |  | | | | CS SSF 11 | | 988 | |
| CS Lymph Nodes |  | | | | CS SSF 12 | | 988 | |
| CS Lymph Nodes Eval |  | | | | CS SSF 13 | | 988 | |
| Regional Nodes Positive |  | | | | CS SSF 14 | | 988 | |
| Regional Nodes Examined |  | | | | CS SSF 15 | | 988 | |
| CS Mets at Dx |  | | | | CS SSF 16 | | 988 | |
| CS Mets Eval |  | | | | CS SSF 17 | | 988 | |
| CS SSF 1 |  | | | | CS SSF 18 | | 988 | |
| CS SSF 2 |  | | | | CS SSF 19 | | 988 | |
| CS SSF 3 |  | | | | CS SSF 20 | | 988 | |
| CS SSF 4 |  | | | | CS SSF 21 | | 988 | |
| CS SSF 5 |  | | | | CS SSF 22 | | 988 | |
| CS SSF 6 |  | | | | CS SSF 23 | | 988 | |
| CS SSF 7 |  | | | | CS SSF 24 | | 988 | |
| CS SSF 8 |  | | | | CS SSF 25 | | 988 | |
| Summary Stage |  | | | | Derived AJCC TNM Stage (indicate c or p in the space before the T, N, or M) | |  | |
| Clinical AJCC TNM Stage |  | | | | Pathologic AJCC TNM Stage | |  | |
| **Treatment** | | | | | | | | |
| Diagnostic Staging Procedure | | |  |  | | | |  |
| **Surgery Codes** | | |  | **Radiation Codes** | | | |  |
| Surgical Procedure of Primary Site | | |  | Radiation Treatment Volume | | | |  |
| Scope of Regional Lymph Node Surgery | | |  | Regional Treatment Modality | | | |  |
| Surgical Procedure/ Other Site | | |  | Regional Dose | | | |  |
| **Systemic Therapy Codes** | | |  | Boost Treatment Modality | | | |  |
| Chemotherapy | | |  | Boost Dose | | | |  |
| Hormone Therapy | | |  | Number of Treatments to Volume | | | |  |
| Immunotherapy | | |  | Reason No Radiation | | | |  |
| Hematologic Transplant/Endocrine Procedure | | |  | Radiation/Surgery Sequence | | | |  |
| Systemic/Surgery Sequence | | |  |  | | | |  |

**CASE SCENARIO 3**

8/9/2013 HISTORY: 64 year-old white female presents with a 2 month history of a lesion on the right upper arm. No palpable regional lymph nodes.

8/9/2013 Pathology Report: Excisional biopsy of skin of right upper arm: 3.0 cm nodule; malignant melanoma, nodular type; Breslow measurement 11.80 mm; Clark level 4; extensive ulceration; no regression; mitotic index 10/mm2; no LVI; no satellite lesions; positive margin (deep margin); unknown vertical growth phase.

8/10/2013 LDH: 351 Normal Range-Female: 46-100 IU/L Male: 46-232 IU/L

8/15/2013 LDH: 357 Normal Range-Female: 46-100 IU/L Male: 46-232 IU/L

9/10/2013 PET/CT: 2.0 cm subcutaneous nodule on right chest revealing abnormal FDG accumulation (SUV 5.8). This is highly suspicious for malignancy. Subcutaneous nodule in left lower abdomen, probably non-malignant etiology (no increased FDG uptake).

10/1/2013 CT Abdomen/Pelvis: Subcutaneous nodule in left lower abdomen is unchanged, but it may represent enlarged lymph nodes. No other abnormalities are noted.

10/1/2013 CT of brain: No metastatic disease.

10/21/2013 Pathology Report: Wide local excision of right upper arm lesion with 2.5 cm margins, excision of subcutaneous lesion on the right chest wall, and right axillary sentinel lymph node biopsy

* Wide excision right upper arm: Residual deep dermal subcutaneous mass of malignant melanoma measuring 3.4mm. A 2.5 cm margin of healthy tissue is present.
* Right chest wall excision: 5 cm lesion subcutaneous lesion, metastatic malignant melanoma. Positive deep margin.
* Sentinel node biopsy: axillary soft tissue metastasis widely free from peripheral/deep margins; 0/8 lymph nodes, negative IHC.

ONCOLOGY: Interferon started 11/26/13

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 3 Worksheet** | | | | | | | | |
| **Primary Site C\_\_ \_\_.\_\_** | | **Morphology \_\_ \_\_ \_\_ \_\_/\_\_ \_\_** | | | | **Laterality \_\_** | | |
| **Stage/ Prognostic Factors** | | | | | | | | |
| CS Tumor Size |  | | | | CS SSF 9 | | 988 | |
| CS Extension |  | | | | CS SSF 10 | | 988 | |
| CS Tumor Size/Ext Eval |  | | | | CS SSF 11 | | 988 | |
| CS Lymph Nodes |  | | | | CS SSF 12 | | 988 | |
| CS Lymph Nodes Eval |  | | | | CS SSF 13 | | 988 | |
| Regional Nodes Positive |  | | | | CS SSF 14 | | 988 | |
| Regional Nodes Examined |  | | | | CS SSF 15 | | 988 | |
| CS Mets at Dx |  | | | | CS SSF 16 | | 988 | |
| CS Mets Eval |  | | | | CS SSF 17 | | 988 | |
| CS SSF 1 |  | | | | CS SSF 18 | | 988 | |
| CS SSF 2 |  | | | | CS SSF 19 | | 988 | |
| CS SSF 3 |  | | | | CS SSF 20 | | 988 | |
| CS SSF 4 |  | | | | CS SSF 21 | | 988 | |
| CS SSF 5 |  | | | | CS SSF 22 | | 988 | |
| CS SSF 6 |  | | | | CS SSF 23 | | 988 | |
| CS SSF 7 |  | | | | CS SSF 24 | | 988 | |
| CS SSF 8 |  | | | | CS SSF 25 | | 988 | |
| Summary Stage |  | | | | Derived AJCC TNM Stage (indicate c or p in the space before the T, N, or M) | |  | |
| Clinical AJCC TNM Stage |  | | | | Pathologic AJCC TNM Stage | |  | |
| **Treatment** | | | | | | | | |
| Diagnostic Staging Procedure | | |  |  | | | |  |
| **Surgery Codes** | | |  | **Radiation Codes** | | | |  |
| Surgical Procedure of Primary Site | | |  | Radiation Treatment Volume | | | |  |
| Scope of Regional Lymph Node Surgery | | |  | Regional Treatment Modality | | | |  |
| Surgical Procedure/ Other Site | | |  | Regional Dose | | | |  |
| **Systemic Therapy Codes** | | |  | Boost Treatment Modality | | | |  |
| Chemotherapy | | |  | Boost Dose | | | |  |
| Hormone Therapy | | |  | Number of Treatments to Volume | | | |  |
| Immunotherapy | | |  | Reason No Radiation | | | |  |
| Hematologic Transplant/Endocrine Procedure | | |  | Radiation/Surgery Sequence | | | |  |
| Systemic/Surgery Sequence | | |  |  | | | |  |

**CASE SCENARIO 4**

4/24/2013 HISTORY: 49 year-old white female presented with history of a mole-like lesion on her right upper back that is now increasing in size and bleeding. Axillary lymphadenopathy is not present.

4/24/2013 Pathology Report: Excisional biopsy of skin of back: Malignant melanoma, superficial spreading type; Clark level IV; Breslow thickness 1.32 mm; ulceration present; focal regression; mitotic index 1/mm2.

5/16/2013 Pathology Report: Sentinel lymph node biopsy and wide local excision of melanoma.

* Wide excision No residual melanoma; 2cm negative margins
* Sentinel lymph node biopsy: 1 sentinel node involved by melanoma, microscopic focus is 0.2 mm; IHC staining confirms sentinel lymph node micrometastasis.

5/30/2013 Pathology Report:

* Right axillary lymph node dissection: 0/20 lymph nodes positive.

6/14/13 CT of Abdomen/Pelvis: Indeterminate luceny in body of T2 (no uptake in PET/CT) and indeterminate left upper lobe lung nodule (no uptake on PET) as well as right adrenal gland nodule.

6/14/13 MRI Brain: No metastatic disease.

8/1/13 Oncology Consult: Patient is not a candidate for interferon or any type of clinical trial due to her comorbidities. Patient will be followed up with scans.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case Scenario 4 Worksheet** | | | | | | | | |
| **Primary Site C\_\_ \_\_.\_\_** | | **Morphology \_\_ \_\_ \_\_ \_\_/\_\_ \_\_** | | | | **Laterality \_\_** | | |
| **Stage/ Prognostic Factors** | | | | | | | | |
| CS Tumor Size |  | | | | CS SSF 9 | | 988 | |
| CS Extension |  | | | | CS SSF 10 | | 988 | |
| CS Tumor Size/Ext Eval |  | | | | CS SSF 11 | | 988 | |
| CS Lymph Nodes |  | | | | CS SSF 12 | | 988 | |
| CS Lymph Nodes Eval |  | | | | CS SSF 13 | | 988 | |
| Regional Nodes Positive |  | | | | CS SSF 14 | | 988 | |
| Regional Nodes Examined |  | | | | CS SSF 15 | | 988 | |
| CS Mets at Dx |  | | | | CS SSF 16 | | 988 | |
| CS Mets Eval |  | | | | CS SSF 17 | | 988 | |
| CS SSF 1 |  | | | | CS SSF 18 | | 988 | |
| CS SSF 2 |  | | | | CS SSF 19 | | 988 | |
| CS SSF 3 |  | | | | CS SSF 20 | | 988 | |
| CS SSF 4 |  | | | | CS SSF 21 | | 988 | |
| CS SSF 5 |  | | | | CS SSF 22 | | 988 | |
| CS SSF 6 |  | | | | CS SSF 23 | | 988 | |
| CS SSF 7 |  | | | | CS SSF 24 | | 988 | |
| CS SSF 8 |  | | | | CS SSF 25 | | 988 | |
| Summary Stage |  | | | | Derived AJCC TNM Stage (indicate c or p in the space before the T, N, or M) | |  | |
| Clinical AJCC TNM Stage |  | | | | Pathologic AJCC TNM Stage | |  | |
| **Treatment** | | | | | | | | |
| Diagnostic Staging Procedure | | |  |  | | | |  |
| **Surgery Codes** | | |  | **Radiation Codes** | | | |  |
| Surgical Procedure of Primary Site | | |  | Radiation Treatment Volume | | | |  |
| Scope of Regional Lymph Node Surgery | | |  | Regional Treatment Modality | | | |  |
| Surgical Procedure/ Other Site | | |  | Regional Dose | | | |  |
| **Systemic Therapy Codes** | | |  | Boost Treatment Modality | | | |  |
| Chemotherapy | | |  | Boost Dose | | | |  |
| Hormone Therapy | | |  | Number of Treatments to Volume | | | |  |
| Immunotherapy | | |  | Reason No Radiation | | | |  |
| Hematologic Transplant/Endocrine Procedure | | |  | Radiation/Surgery Sequence | | | |  |
| Systemic/Surgery Sequence | | |  |  | | | |  |